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ABSTRACT 
Objective: The objective of this study was to evaluate the utilization and cost pattern of AMAs (Antimicrobial Agents) in the Medical ICU of a 
tertiary care teaching hospital, and to determine the predictor of antimicrobial number per day.  
Methods: A prospective cross-sectional study was carried out and a total of 101 patients were studied. The drugs were classified into different 
groups according to the World Health Organization’s ATC (Anatomical Therapeutic Chemical) Classification System.  
Results: The mean [95% confidence interval (CI)] duration of ICU stay was 7.11 (5.70-8.52) days and the mortality rate in the ICU was 42.6%. The 
AMAs DDD (Defined Daily Dose) per 100 patient days and number of AMAs per prescription were 296.64 and 2.65, respectively. Piperacillin-
tazobactam was the most commonly utilized AMAs followed by metronidazole, meropenem, fluconazole, and colistin. The mean number [95% CI] of 
AMAs, DDD, and cost (INR) per patient were 18.82 (14.05-23.59), 21.09 (15.36-26.81) and 25,827 (18,716-32,939) respectively. The AMAs 
constituted 88.53% of the total treatment cost. Meropenem was the most costly AMA (32.10% of the total AMAs cost) followed by imipenem-
cilastatin (20.50%), colistin (14.65%), piperacillin-tazobactam (8.40%), and clindamycin (4.47%). The independent predictor for the antimicrobial 
number per day was acute physiology and chronic health evaluation II (APACHE-II) score at admission and nosocomial infections. 
Conclusion: The AMAs, DDD per 100 patient days, and number per prescription were higher. This leads to a higher cost of AMAs per patient and the AMAs 
cost out of the total cost as compared to previous studies. We suggest, there is a need to formulate and implement an antimicrobial restriction policy. 
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INTRODUCTION 
World Health Organization (WHO) has defined drug utilization 
research as “the marketing, distribution, prescription, and use of 
drugs in society, with special emphasis on the resulting medical, 
social, and economic consequences” [1]. 
The patients admitted to the medical intensive care units (ICUs) are 
generally seriously ill or require specialized care and close 
monitoring. They are predisposed to get infected either due to 
various invasive procedures or secondary to nosocomial infection. 
The antimicrobial agents (AMAs) utilization rate is high in ICUs as 
compare to the general wards [2]. Multiple broad-spectrum AMAs 
are usually administered empirically to these patients and this 
usually leads to the inappropriate use of AMAs [3-5]. The higher 
utilization and inappropriate use of AMAs lead to the development 
of antimicrobial resistance (AMR) in the ICUs [4, 5]. The AMR is the 
major determinant of therapeutic outcomes [6]. 
The AMR is continuously increasing globally and leading cause of 
public health threats and economic consequences [7, 8]. The rational 
utilization of AMAs will not only reduce the costs but also reduce the 
incidence of AMR that leads to a better prognosis [9].  
There is limited data from Indian ICUs on antimicrobial agent’s 
prescription, utilization patterns, and cost in Indian ICUs. Regular 
prescription audit and feedback can reduce the irrational use of AMAs 
in ICU. We have aimed to assess the utilization pattern and cost 
analysis of AMAs in the Medical ICU of a tertiary care teaching hospital.  
MATERIALS AND METHODS 
Study subjects  
This study was a prospective observational study. It was conducted 
at 12 bedded Intensive Care Unit (ICU) of the Department of 
Medicine at King George’s Medical University, Lucknow. The study is 
approved by the institutional ethics committee (Reference code: 
74thECM II-B Thesis/P17). All the patients admitted to the medical 
ICU, who were prescribed at least one antimicrobial agent, were 
included in the study. Those who did not give informed consent or 
gave incomplete data and patients who stayed for less than 24 h in 
the ICU, were excluded from the study. The data were collected 
prospectively for 3months (1/05/2016 to 31/07/2016). Written 
informed consent was taken from the patients or parents/guardians 
of the patients. A total of 101 patients were recruited based on 
exclusion and inclusion criteria. 
The demographic variables, vitals, acute physiology and chronic health 
evaluation II (APACHE II) score at admission, duration of ICU stay, and 
the diagnosis was recorded in the case record form. All drugs listed on 
the prescription were recorded. The dose, frequency, duration, and 
route of administration of all drugs were recorded until the patient got 
shifted to the ward, got discharged, or got expired. The drugs are given 
in infusions (barring AMAs), intravenous fluids, sedatives, atropine, 
and insulin, which were not included in the analysis. 
The drugs were classified into different groups according to the 
WHO-ATC classification. Antimicrobials are all substances of ATC 
group J (anti-infectives for systemic use, including antibacterials for 
systemic use, antimycotics for systemic use, antimycobacterial, 
antivirals for systemic use, immune sera, immunoglobulin’s, and 
vaccines) and group P (Antiparasitic products include 
antiprotozoals, anthelmintics, and ectoparasiticides) [10, 11]. 
The following indicators were calculated:  
1. DDD of each prescribed drug was calculated. 
2. DDD per 100 patient days: Patient days are the number of days 
for which inpatients are hospitalized. The days of admission, but not 
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the day of discharge, are counted as patient days. For example, if 
both the admission and discharge occur on the same day, this is 
counted as 1 patient day. For hospital inpatients, DDD/100 patient 
days provide a rough estimate of drug consumption. 
DDD/100 patient days =
Total consumption in DDDs 
Number of patient days
 ×  100 
DU90% index-the DU90% was calculated by ranking the antimicrobial 
by volume of DDD, summing the DDD for these drugs, and then 
determining how many drugs accounted for 90% of drug use. 
The brand name of drugs was decoded using the CIMS drug manual 
(Volume-6, Issue-67). 
Statistical analysis 
Percentage usage and DDD/100 Patient days were calculated. 
Continuous data are presented as mean (95% CI) and were analyzed 
using the Mann–Whitney U test. A multiple regression binary logistic 
with forward conditional elimination was used to examine the effect 
of covariates on antimicrobial numbers per day and to identify 
independent predictors of the antimicrobial number per day. 
Covariates with p ≤ 0. 10 in the respective univariate analysis were 
entered into these models. Results of binary logistic regression are 
reported as odds ratios with corresponding 95% CI. A two-tailed 
p<0.05 was considered statistically significant. All analyses were 
performed with SPSS statistical software package (version 20, IBM 
Inc., Armonk, NY, USA). 
RESULTS 
Patient characteristics 
A total of 101 patients were included in the study. Of these 101 
patients, 58 (57.4%) were male and 43 (42.6%) were female. The 
mean (95% CI) age of the patients was 39.21 (35.12-43.30) years. 
The mean (95% CI) APACHE II score at the admission of the patients 
was 17.88 (16.13-19.63). The total patient days were 718 d and the 
mean (95% CI) length of stay (LOS) stay was 7.11 (5.70-8.52) days. 
The comorbidity was present in 51 (50.50%) patients. Out of 101 
patients, 63 (62.4%) patients were on the ventilator at any time 
during the hospital stay. The nosocomial infection developed in 32 
(31.7%) patients. The mortality rate in the ICU was 42.6%.  
Respiratory illness (24.75%) was the most common cause for 
admission in the ICU followed by shock/MODS (Multiple Organ 
Dysfunction Syndrome) (18.81%), poisoning (14.85%), central 
nervous system disease (10.89%), gastrointestinal tract and 
hepatobiliary system (9.90%), pyrexia (6.93%), cardiovascular 
system disease (5.94%), renal system disease (5.94%) and 
endocrine system disease (1.98%). 
In 718 prescriptions of 101 patients, a total of 5015 drugs and 1901 
AMAs were prescribed with an average of 6.98 drugs per 
prescription and 2.65 AMAs per prescription. The AMAs constituted 
37.90% of the total number of drugs prescribed. 
The total consumption of drugs in this study was 5,535.19 DDD, 
where antimicrobials (group J and P) constituted the most 
utilized single group with 2,129.90 DDD (38.47%) of all drugs 
utilized and 3,405.29 DDD (61.53%) by other groups. The total 
consumption of drugs in DDD/100 patient days was 770.92, 
where antimicrobials (group J and P) constituted 296.64 
DDD/100 patient days and 474.28 DDD/100 patient days by 
other groups. 
The total drug cost in ICU was 2,946,513 INR, where 
antimicrobials (group J and P) constituted the costliest group 
with 2,608,591 INR (88.53%) of all drug costs and 337,922 INR 
(11.47%) by other groups. The total drug cost in terms of 
INR/100 patient days was 410,377 INR/100 patient days, where 
antimicrobials (group J and P) constituted 363,313 INR/100 
patient days and 47,064 INR/100 patient days by other groups. 
The total drug and antimicrobials cost per patient was 29,173 
and 25,827 INR per patient, respectively [table 1]. 
  
Table 1: Total drug and antimicrobial DDD, number, and cost per patient 
Total drug DDD per patient 54.80 (41.19-68.41) 
Antimicrobial DDD per patient 21.09 (15.36-26.81) 
Total drug number per patient 49.65 (36.74-62.57) 
Antimicrobial number per patient 18.82 (14.05-23.59) 
Total drug cost per patient (INR) 29,173 (21,524-36,822) 
Antimicrobial cost per patient (INR) 25,827 (18,716-32,939) 
Values are expressed in mean (95% confidence interval) 
 
Table 2: Comparison of antimicrobial DDD, number, and cost per patient based on various factors 
Patients  Antimicrobials DDD per patient Antimicrobial no per patient Antimicrobials cost per patient 
Survived (N=58) 14.26 (9.65-18.87) 13.45 (9.13-17.77) 18,223 (11,007-25,440) 
Expired (N=43) 30.30 (18.64-41.96) 26.07 (16.69-35.45) 36,083 (22,740-49,426) 
P value 0.010* 0.006* 0.010* 
Co-morbidity present (N=51) 24.49 (14.38-34.60) 20.58 (12.50-28.66) 30,109 (18,324-41,894) 
Co-morbidity absent (N=50) 17.75 (11.99-23.52) 17.10 (11.70-22.50) 21,629 (13,315-29,944) 
P value 0.336 0.456 0.109 
Ventilated (N=63) 28.44 (19.78-37.11) 24.79 (17.59-32.00) 35671 (25,083-46,260) 
Not ventilated (N=38) 8.90 (6.68-11.11) 8.92 (6.75-11.10) 9507 (6,114-12,900) 
P value 0.001* 0.001* 0.001* 
Nosocomial infection 
developed (N=32) 
46.12 (31.88-60.36) 40.56 (28.90-52.22) 54668 (38,522-70,814) 
Nosocomial infection not 
developed (N=69) 
9.48 (7.14-11.81) 8.74 (6.95-10.53) 12452 (75,22-17,832) 
P value <0.001* <0.001* <0.001* 
APACHE II score ≤15 
(N=45) 
10.67 (6.88-14.47) 10.51 (6.87-14.14) 13,884 (6,620-21,148) 
APACHE II Score>15 (n=56) 29.45 (20.02-38.90) 25.50 (17.73-33.27) 35,424 (24,443-46,405) 
P value <0.001* <0.001* <0.001* 
Values are expressed in mean (95% confidence interval)*Pvalue<0.05 is considered significant. NS: not significant. 
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Table 3: AMAs consumption (Group J and P) measured in DDD 
ATC code Antimicrobial groups DDD DDD/100PD % of total AMAs DDD 
J01AA12  Tigecycline (16th) 37.00 5.15 1.74 
J01CR02  Amoxicillin and enzyme inhibitor 22.50 3.13 1.06 
J01CR05 Piperacillin-tazobactam (1st) 209.43 29.17 9.84 
J01DD04 Ceftriaxone (9th) 110.00 15.32 5.16 
J01DD12 Cefoperazone (14th) 49.00 6.82 2.30 
J01DH02 Meropenem (3rd) 189.00 26.32 8.87 
J01DH51 Imipenem-cilastatin (7th) 140.75 19.60 6.61 
J01FA10 Azithromycin 33.00 4.60 1.55 
J01FF01 Clindamycin (6th) 150.67 20.98 7.07 
J01GB01 Tobramycin (12th) 78.00 10.86 3.66 
J01GB06 Amikacin (11th) 86.75 12.08 4.07 
J01MA12 Levofloxacin (10th) 91.50 12.74 4.30 
J01MA14  Moxifloxacin (15th) 43.00 5.99 2.02 
J01XA01 Vancomycin 21.40 2.98 1.00 
J01XA02 Teicoplanin (8th) 122.00 16.99 5.73 
J01XB01 Colistin (5th) 167.67 23.35 7.87 
J01XD01 Metronidazole (2nd) 198.87 27.70 9.34 
J01XX08 Linezolid (13th) 71.00 9.89 3.33 
J02AC01 Fluconazole (4th) 172.00 23.96 8.08 
 Others  136.37 19.01 6.40 
 Total 2129.91 296.64 100.00 
Others represent the antimicrobial agents with less than 1% of total DDD.  
 
Table 4: AMAs cost (Group J and P) measured in Indian Rupees (INR) 
ATC Code Antimicrobial group Total cost Total cost/100PD % of total AMAs Cost 
J01CR05 Piperacillin-tazobactam (4th) 219,062.29 30,510.07 8.40 
J01DD12 Cefoperazone (8th) 60,270.00 8,394.15 2.31 
J01DD62 Cefoperazone-sulbactam 29,754.00 4,144.01 1.14 
J01DH02 Meropenem (1st) 837,270 116,611.42 32.10 
J01DH51 Imipenem-cilastatin (2nd) 534,850.00 74,491.64 20.50 
J01FF01 Clindamycin (5th) 116,616.00 16,241.78 4.47 
J01XA01 Vancomycin 29,232.40 4,071.36 1.12 
J01XA02 Teicoplanin (6th) 108,702.00 15,139.55 4.17 
J01XB01 Colistin (3rd) 382,280.00 53,242.34 14.65 
J01XX08 Linezolid (9th) 49,842.00 6,941.78 1.91 
J05AB01 Aciclovir (7th) 60,800.00 8,467.97 2.33 
 Others 179,912 25,057.45 6.9 
 Total 2,608,591 363,313.45 100.00 
Others represent the antimicrobial agents with less than 1% of the total cost.  
 
Table 5: Predictors of multiple antimicrobial prescribing using binary logistic regression analysis 
 Antimicrobial prescriptions Univariate Multivariate 
Predictors ≤2 antimicrobial number 
per day number (%) 
>2 antimicrobial number 
per day number (%) 


































































































































Logistic regression analysis with the forward conditional elimination was used with entry criteria of p ≤ 0.10 and a removal criterion of 
p>0.10.*Significant OR=odd’s ratio, CI=confidence interval, *Pvalue<0.05 is considered significant. Input variables in Multivariate binary logistic 
regression analysis: Age, APACHE-II, Comorbidity, Nosocomial infection, and Length of stay. 
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The antimicrobials DDD, number, and cost per patient was 
significantly higher in expired (vs. survived), ventilated (vs. not 
ventilated), patients who developed a nosocomial infection (vs. not 
developed nosocomial infection) and APACHE II score>15 (vs. 
APACHE II Score ≤15) [table 2]. 
A total of 35 antimicrobial agents were prescribed. There were 16 
AMAs in the DU 90% segment out of 35 used AMAs. The DU90% index 
placed piperacillin-tazobactam at 1stplace with 209.43 DDD (9.84%). 
The metronidazole came 2ndwith 198.87DDD (9.34%), followed by 
meropenem (3rd) with 189 DDD (8.87%), fluconazole (4th) with 172 
DDD (8.08%), and colistin (5th) with 167.67DDD (7.87%). The AMAs 
utilization in terms of DDD/100 patient days for piperacillin-
tazobactam, metronidazole, meropenem, fluconazole, and colistin 
were 29.17, 27.70, 26.32, 23.96, and 23.35, respectively [table 3]. 
The 9 AMAs constituted 90% of the total AMAs cost. Meropenem 
was the costliest AMA (32.10% of the total AMAs cost) followed by 
imipenem-cilastatin (20.50%), colistin (14.65%), piperacillin-
tazobactam (8.40%), and clindamycin (4.47%). The AMAs cost in 
terms of INR/100 patient days for meropenem, imipenem-cilastatin, 
colistin, piperacillin-tazobactam, and clindamycin were 116,611 
INR/100 patient days, 74,491 INR/100 patient days, 53,242 
INR/100 patient days, 30,510 INR/100 patient days, and 16,241 
INR/100 patient days, respectively [table 4]. 
On analyzing the indication of antimicrobials therapy, it was found 
that out of 2129.91 DDD of AMAs, 1479.25 DDD (69.45%) was 
prescribed empirically followed by definitive 590.80 DDD (27.74%) 
and prophylactically 59.86 DDD (2.81%). 
On univariate binary logistic regression analysis, the significant factors 
for the antimicrobial number per day were age<45 y, APACHE II score 
at admission>15, comorbidity, nosocomial infection, and length of 
stay>7 d. The multivariate analysis showed that the independent 
predictor for the antimicrobial number per day was the APACHE II 
Score at admission>15 and nosocomial infection [table 5].  
DISCUSSION 
Male preponderance (57.4%) was observed in the present study and 
the male: female ratio was following the previous studies [12-15]. In 
contrast, a study had reported an equal percentage of male and 
female patients [16]. The mean age of the patients in our study was 
39.21 y, which was less than the mean age reported previously 
(44.62 to 60.30 y) [12-15, 17, 18]. The mean (95% CI) length of stay 
(LOS) in our study was 7.11 (5.70-8.52) days which was comparable 
to the other studies [13-15, 17, 19]. In other studies, the mean LOS in 
ICU was found to be in the range of 4.0 to 7.3 d. The mortality rate 
was found to be 42.6%, which was slightly higher compared to other 
studies. In other studies, the mortality in ICU was found to be in the 
range of 12.0 to 39.5% [15-17]. But in a study conducted by Patel et 
al. (2013), the mortality rate in patients with medical indication was 
high (71.58%) [13]. 
Utilization of antimicrobial agent (quantitatively in DDD) 
The AMAs consumption rate was 296.64 DDD/100 patient days, 
much higher compared to the two Indian studies (36.52 and 148.97 
DDD/100 patient-days) [13, 15]. In a meta-analysis conducted by 
Bitterman et al. (2016), the antibacterial consumption was highest 
in intensive care units with a value of 156.3 DDD/100 hospital days 
(95% CI: 147.2 to 165.3) [20, ]. In the ICARE Project in 40 US 
hospitals, the antibiotic consumption rate in ICU ranged from 41.3 to 
92.7 DDD per 100 patient days [21]. 
The total number of AMAs used was 35, out of them 16were in the 
DU90% segment. Adeli et al. (2015) studied the antibiotics use 
patterns in intensive care units of five hospitals, the number of 
AMAs in the DU90% segment ranged from 3 to 12 [22]. 
The most commonly utilized AMAs in our study were piperacillin-
tazobactam followed by metronidazole, meropenem, fluconazole, and 
colistin [table 3]. In a study by Williams et al. (2011) from North India, 
the five most utilized AMAs were 3rd generation cephalosporins, 
meropenem, metronidazole, levofloxacin, and ceftriaxone [18]. In a 
study by Anand et al. (2016) from South India, the five most utilized 
AMAs were ceftriaxone, piperacillin-tazobactam, metronidazole, 
linezolid, and amoxicillin-clavulanic acid [15]. 
In a study in 35 ICUs of Germany, the penicillins with a beta-lactamase 
inhibitor, quinolones, and second-generation cephalosporins were the 
most commonly utilized AMAs while a study from Latin America, the 
carbapenems (imipenem or meropenem), vancomycin, piperacillin-
tazobactam, and broad-spectrum cephalosporins were the most 
frequently used AMAs [14, 23]. 
Cost of antimicrobial agent 
The total cost of all drugs and AMAs used throughout the study period 
was 2,946,513 INR and 2,608,591 INR, respectively. The AMAs 
constituted 88.53% of the total cost. Meropenem constitutes the major 
portion of the total cost of all AMAs used (32.10%) like other studies 
[18, 20-24] but in one study from Gujrat, the piperacillin-tazobactam 
constitute the major portion of the total cost of all AMAs used [15]. The 
top five AMAs utilized constitute 80.12% of the total AMA cost. The 
next four most expensive AMAs utilized were imipenem-cilastatin 
(20.50%), colistin (14.65%), piperacillin-tazobactam (8.40%), and 
clindamycin (4.47%). In other studies, AMAs cost ranged from 40% to 
73.2% of the total cost [12, 13, 18, 25]. 
In our study, the total cost and the AMAs cost per patient were 
29,173 INR (435.30$) and 25,827 INR (385.37 $), respectively [table 
1]. In other Indian studies, the mean antimicrobial cost per patient 
was in the range of 1,958 to 4,364 INR [15, 18, 25]. But a study 
conducted in Maharashtra by Mangrulkar et al. (2012), the mean 
antimicrobial cost per patient was 39,328 INR [26]. 
The drug cost is enormously varied across the globe so comparisons 
of AMA’s cost among countries may be deceptive. In our study AMA 
cost per 100 patient days was 363,313 INR. The daily AMAs cost in 
our study was 3,633 INR (54$) which was lower as compared to 
studies conducted in Belgium (114€) and Turkey (89$) [24, 27]. 
Prescription of antimicrobial agent (frequency) 
In our study, a total of 5015 drugs and 1901 AMAs were prescribed 
in the 718 prescriptions, which was an average of 6.98 drugs per 
prescription and 2.65 AMAs per prescription, AMAs constituted 
37.90% of the total number of drugs prescribed. In other studies, the 
mean number of drugs per prescription was in the range of 6.23 to 
11.6 [16, 18, 25, 28]. The mean number of AMAs per prescription 
from other studies was in the range of 1.73 to 2.09 [15, 18, 24]. The 
percentage of AMAs number out of total drugs in two Indian studies 
was 20.97% and 33.54% [18, 25]. 
CONCLUSION 
The AMAs consumption rate (DDD per 100 patient-days) was higher 
in the studied medical ICU. The number of AMAs per prescription was 
higher in our study compared to other studies. The cost of AMAs per 
patient and the AMAs cost out of the total cost was quite higher in 
comparison to the previous studies. The antimicrobials DDD, number, 
and cost per patient were significantly higher in expired (vs. survived), 
ventilated (vs. not ventilated) patients, and patients who developed a 
nosocomial infection (vs. not developed nosocomial infection). The 
APACHE-II score at admission and nosocomial infection was the 
independent predictor of antimicrobial number per day.  
RECOMMENDATIONS 
There is a need to formulate and implement a strict antimicrobial 
restriction policy. There should be a regular audit to increase 
adherence to policy/protocol. An antimicrobial stewardship 
program should be implemented. The possible inclusion of clinical 
pharmacologists and microbiologists in the auditing team can prove 
helpful in the rational use of AMAs. 
LIMITATIONS OF THE STUDY 
The period of the study was limited (3 mo). We did not check the 
rationality of prescribed AMAs. The study was conducted in the 
medical ICU only and we did not include other ICUs 
(surgical/neonatal/pediatric) of the hospital. DDD values do not 
take into account the frequently encountered clinical situation of 
dose adjustments (hepatic impairment, renal impairment, etc.). 
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